The short version of reversed-phase HPLC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-06 and is reviewed periodically as new material appears.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Aseptic technique recommended |
| Post-reconstitution storage | 2–8 °C short term; frozen for longer periods | Avoid repeated freeze-thaw cycles |
| Typical purity assay | Reversed-phase HPLC | Peak area used to estimate purity |
| Identity confirmation | Mass measurement | Compares observed value with expected mass |
| Main degradation routes | Hydrolysis and oxidation | Accelerated by heat and extreme pH |
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
DNA expression requires the transfection of suitable host cells. Typically, either bacterial, yeast, insect, or mammalian cells (such as human embryonic kidney cells or Chinese hamster ovary cells) are used as host cells. Following transplantation into the host organism, the foreign DNA contained within the recombinant DNA construct may or may not be expressed. That is, the DNA may simply be replicated without expression, or it may be transcribed and translated and a recombinant protein is produced. Generally speaking, expression of a foreign gene requires restructuring the gene to include sequences that are required for producing an mRNA molecule that can be used by the host's translational apparatus (e.g. promoter, translational initiation signal, and transcriptional terminator). Specific changes to the host organism may be made to improve expression of the ectopic gene. In addition, changes may be needed to the coding sequences as well, to optimize translation, make the protein soluble, direct the recombinant protein to the proper cellular or extracellular location, and stabilize the protein from degradation.
Actin filament disassembly The immobilization by interpenetration of actin filaments results from two distinct ABP families. The gelsolin protein family is believed to be the most efficient in the disruption of actin filaments and is considered a "strong severing protein". These proteins respond to an increase in Ca2+ and cap the "barbed end" of the recently severed F-actin. The increased level of Ca2+ may also destabilize the actin-filament network by interfering with the binding of crosslinking proteins. The ADF/Cofilin protein family also serves to severe actin-filament networks through the weak severing of actin networks. This form of weak severing does not tightly cap the "barbed ends" but does allow for the disassociation of actin monomers and thus the disassembly of F-actin. Monomer sequestration that prevents spontaneous nucleation Exists as the turnover point in the actin remodeling cycle. The proteins thymosin and profilin prevent the spontaneous nucleation of new actin trimers. The absence or inhibition of these proteins results in the cell's ability to commence the actin remodeling cycle and produce elongated F-actin.
Coupling MALS with an in-line concentration detector following a sample separation means like SEC permits the calculation of the molar mass of the eluting sample in addition to its root-mean-square radius. The figure below represents a chromatographic separation of BSA aggregates. The 90° light scattering signal from a MALS detector and the molar mass values for each elution slice are shown.
Chemical ligation is the chemoselective condensation of unprotected peptide segments enabled by the formation of a non-native bond at the ligation site. Chemical ligation is usually carried out in aqueous solution. Multiple consecutive chemical ligation reactions can be used to make proteins of the typical size found in nature, i.e. with polypeptide chains containing 200–300 amino acids, produced by total synthesis.
Sources: en.wikipedia.org
Of the 90 patients, four required surgical intervention due to nodules in the lips. Gore-Tex implants. In medical uses, Gore-Tex is known as EPTFE, or expanded polytetrafluoroethylene and, commercially as Advanta, UltraSoft, and SoftForm. The EPTFE is delivered to surgeons in strips that are 1⁄16 inch (1.6 mm) and 3⁄16 inch (4.8 mm) diameter tubes.
Collagen alpha-2(I) chain is a protein that in humans is encoded by the COL1A2 gene. This gene encodes one of the chains for type I collagen, the fibrillar collagen found in most connective tissues. Mutations in this gene are associated with osteogenesis imperfecta, Cardiac-valvular and Arthrochlasia type Ehlers–Danlos syndrome, idiopathic osteoporosis, and atypical Marfan syndrome. Symptoms associated with mutations in this gene, however, tend to be less severe than mutations in the gene for alpha-1 type I collagen, since alpha-2 is less abundant. Multiple messages for this gene result from multiple polyadenylation signals, a feature shared by most of the other collagen genes.
== Management == There is no cure for vascular EDS, and management centers on preventing and treating arterial and organ complications. The beta-blocker celiprolol is the most studied preventive therapy: in a prospective, randomized, open-label, blinded-endpoint trial, celiprolol reduced the incidence of arterial dissection and rupture in patients with vascular EDS, and the trial was stopped early for benefit. Subsequent long-term observational data associated celiprolol treatment with improved survival and a dose-dependent reduction in mortality. Because of the fragility of arterial and other tissues, elective surgery and invasive vascular procedures are approached with caution.
SR-17018 was subsequently assessed in rhesus monkeys and produced analgesic effects in this species that could be reversed by the MOR antagonist naltrexone, whereas respiratory depression could not be assessed due to solubility limitations. While conventional opioids like morphine produced robust itch-scratching behaviors, SR-17018 and buprenorphine only caused mild such effects, suggesting low-efficacy MOR activation. Although SR-17018 was reported to produce very little respiratory depression in mice, a subsequent study using oral administration instead of intraperitoneal administration, with the former having greater bioavailability, unexpectedly found significant respiratory depression with the drug. SR-17018 produced less analgesic tolerance than other MOR agonists in mice. Whereas morphine and oxycodone produced robust tolerance in the hot plate test with chronic administration, SR-17018 produced no or only slight tolerance in this assay depending on the dosage. In addition, whereas morphine caused MOR desensitization in the periaqueductal gray (PAG), a key brain area implicated in the analgesic effects of MOR agonists, SR-17018 produced no desensitization. Similarly, unlike morphine, SR-17018 did not cause upregulation of forskolin-stimulated cAMP accumulation in striatal membranes. Despite the preceding findings however, discontinuation of both morphine and SR-17018 caused withdrawal symptoms in mice, though withdrawal symptoms were lower with SR-17018 compared to morphine.
== Medical uses == Norgestrienone was used in hormonal contraception to prevent pregnancy. It has typically been used as an oral contraceptive at a dosage of 2 mg/day in combination with ethinylestradiol and 350 μ/day when used alone.
Sources: en.wikipedia.org
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.
There is no broadly accepted figure for TB-500. Laboratory practice is short-term storage at 2–8 °C with longer-term aliquots frozen, and degradation is expected to increase with time and temperature. Users typically rely on their own stability checks rather than published data.
Mass measurement provides the clearest confirmation by matching an observed value to the expected one. Reversed-phase chromatography adds a purity estimate through peak integration. Combining both is standard because neither alone establishes identity and purity together.
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.